Precursors of ovarian cancer in the fallopian tube: Serous tubal intraepithelial carcinoma - An update

Journal of Obstetrics and Gynaecology Research

Volumn 41, Issue 1, 2015, Pages 6-11

  Zeppernick, Felix ^a   Meinhold Heerlein, Ivo ^a   Shih, Ie Ming ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

epithelial ovarian cancer; fallopian tube; high grade serous carcinoma; precursor; serous tubal intraepithelial carcinoma

Indexed keywords

ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL PRACTICE; CLINICAL RESEARCH; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; OVARY CANCER; RETROSPECTIVE STUDY; UTERINE TUBE; UTERINE TUBE CARCINOMA; UTERINE TUBE LIGATION; CARCINOMA; FALLOPIAN TUBE NEOPLASMS;

CARCINOMA; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS;

EID: 84920854704     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12550     Document Type: Article

References (38)

1. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305: 2295-2303.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Seidman JD, Cho K, Ronnett BM, et al. Surface epithelial tumors of the ovary. In:, Kurman RJ, Ellenson LH, Ronnett BM, (eds). Blaustein's Pathology of the Female Genital Tract. New York: Springer Verlag, 2011; 679-784.
4. Shih Ie M, Kurman RJ,. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518.
5. Kurman RJ, Shih IeM,. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931.
6. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235-240.
7. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncol 2007; 8: 26-34.
8. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011; 105: 1436-1442.
9. Fathalla MF,. Incessant ovulation-A factor in ovarian neoplasia Lancet 1971; 2: 163.
10. Hu CY, Taymor ML, Hertig AT,. Primary carcinoma of the fallopian tube. Am J Obstet Gyn 1950; 59: 58-67.
11. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456.
12. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236.
13. Kurman RJ,. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 2013; 24 (Suppl 10): x16-x21.
14. Conner JR, Meserve E, Pizer E, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol 2014; 132: 280-286.
15. Crum CP, Herfs M, Ning G, et al. Through the glass darkly: Intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol 2013; 231: 402-412.
16. Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ,. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013; 49: 132-141.
17. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin Am J Surg Pathol 2010; 34: 1407-1416.
18. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100: 58-64.
19. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-3990.
20. Reitsma W, Hollema H, Mourits MJ,. Letter commenting on 'Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol' in Int J Gynecol Cancer 2011; 21: 846-851 by C. Bethan Powell et al. Int J Gynecol Cancer 2012; 22: doi: 10.1097/IGC.0b013e31822d0e91.
21. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
22. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426.
23. Sehdev AS, Kurman RJ, Kuhn E, et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010; 23: 844-855.
24. Perets R, Wyant GA, Muto KW, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013; 24: 751-765.
25. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: An early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010; 34: 829-836.
26. Wethington SL, Park KJ, Soslow RA, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 2013; 23: 1603-1611.
27. Rosenblatt KA, Thomas DB,. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996; 5: 933-935.
28. Rice MS, Murphy MA, Tworoger SS,. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. J Ovarian Res 2012; 5: 13.
29. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012; 22: 1310-1315.
30. Collins IM, Domchek SM, Huntsman DG, et al. The tubal hypothesis of ovarian cancer: Caution needed. Lancet Oncol 2011; 12: 1089-1091.
31. Findley AD, Siedhoff MT, Hobbs KA, et al. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: A pilot randomized controlled trial. Fertil Steril 2013; 100: 1704-1708.
32. Morelli M, Venturella R, Mocciaro R, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere. Gynecol Oncol 2013; 129: 448-451.
33. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5: 167ra4.
34. Hillier SG,. Nonovarian origins of ovarian cancer. Proc Natl Acad Sci U S A 2012; 109: 3608-3609.
35. Barua A, Bitterman P, Abramowicz JS, et al. Histopathology of ovarian tumors in laying hens: A preclinical model of human ovarian cancer. Int J Gynecol Cancer 2009; 19: 531-539.
36. Yu Y, Edassery SL, Barua A, et al. The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors. J Ovarian Res. 2011; 4: 12.
37. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012; 13: 607-615.
38. Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium. JNCI J Natl Cancer Inst 2014; 106: djt431.